Z
Zhenxi Zhang
Researcher at Sanofi Pasteur
Publications - 24
Citations - 2094
Zhenxi Zhang is an academic researcher from Sanofi Pasteur. The author has contributed to research in topics: Virus & Flavivirus. The author has an hindex of 16, co-authored 24 publications receiving 2035 citations.
Papers
More filters
Journal ArticleDOI
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Farshad Guirakhoo,Weltzin Richard A,Thomas J. Chambers,Zhenxi Zhang,Kenneth F. Soike,Marion S. Ratterree,Juan Arroyo,K. Georgakopoulos,John Catalan,Thomas P. Monath +9 more
TL;DR: The high replication efficiency, attenuation phenotype in mice and monkeys, immunogenicity and protective efficacy, and genomic stability of ChimeriVax-D2 justify it as a novel vaccine candidate to be evaluated in humans.
Journal ArticleDOI
Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates
Farshad Guirakhoo,Konstantin V. Pugachev,Zhenxi Zhang,Gwendolyn A. Myers,Inessa S. Levenbook,Ken Draper,Jean Lang,Simeon W. Ocran,Fred Mitchell,Megan Parsons,Nancy V. Brown,Samantha Brandler,C. Fournier,B. Barrere,F. Rizvi,A. Travassos,Richard A. Nichols,Dennis W. Trent,Thomas P. Monath +18 more
TL;DR: This report is the first to demonstrate the safety of a recombinant DEN virus tetravalent vaccine in a formal neurovirulence test, as well as its protective efficacy in a monkey challenge model.
Journal ArticleDOI
Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine
Farshad Guirakhoo,Juan Arroyo,Konstantin V. Pugachev,Chuck Miller,Zhenxi Zhang,Weltzin Richard A,K. Georgakopoulos,John Catalan,Simeon W. Ocran,Kenneth F. Soike,Marion S. Ratterree,Thomas P. Monath +11 more
TL;DR: This is the first recombinant tetravalent dengue vaccine successfully evaluated in nonhuman primates and no statistically significant difference in levels of neutralizing antibodies was observed between YF virus-immune and nonimmune monkeys which received the tetraValent YF/DEN1-4 vaccine or between tetraavalent Yf/DEN 1-4- immune and non immune monkeys which receive the YF-VAX.
Journal ArticleDOI
Immunogenicity, Genetic Stability, and Protective Efficacy of a Recombinant, Chimeric Yellow Fever-Japanese Encephalitis Virus (ChimeriVax-JE) as a Live, Attenuated Vaccine Candidate against Japanese Encephalitis☆
Farshad Guirakhoo,Zhenxi Zhang,Thomas J. Chambers,Simon Delagrave,J. Arroyo,Alan D.T. Barrett,Thomas P. Monath +6 more
TL;DR: Mice inoculated subcutaneously with one dose of ChimeriVax-JE virus were solidly protected against intraperitoneal challenge with a virulent JE virus.
Journal ArticleDOI
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Thomas P. Monath,Kenneth F. Soike,Inessa S. Levenbook,Zhenxi Zhang,Juan Arroyo,Simon Delagrave,Gwendolyn A. Myers,Alan D.T. Barrett,Robert E. Shope,Marion S. Ratterree,Thomas J. Chambers,Farshad Guirakhoo +11 more
TL;DR: The ability of the ChimeriVax-JE to induce a rapid humoral immune response and to protect against a very severe, direct intracerebral virus challenge is demonstrated and will be applicable to control testing of chimaeric seed viruses and vaccines.